| 000 | 00000nam##2200000za#4500 |
| 001 | 9.581216 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20210624191419 |
|---|
| 007 | cr ||||||||||| |
|---|
| 008 | 150406|2014||||xxc|||||o f|0| 0 eng|d |
|---|
| 040 | |aCaOODSP|beng |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aYC17-0/412-15E-PDF |
|---|
| 110 | 1 |aCanada. |bParliament. |bSenate. |bStanding Committee on Social Affairs, Science and Technology. |
|---|
| 245 | 10|aPrescription pharmaceuticals in Canada : |h[electronic resource]|bunintended consequences / |cThe Honourable Kelvin K. Ogilvie, Chair ; The Honourable Art Eggleton, P.C., Deputy Chair. |
|---|
| 260 | |aOttawa - Ontario : |bSenate. |cOctober 2014. |
|---|
| 300 | |a52p.|breferences, photographs |
|---|
| 490 | 1 |aReport of the Standing Senate Committee on Social Affairs, Science and Technology|v[41st Parliament, 2nd Session, 15th report] |
|---|
| 590 | |a14-47|b2014-11-21 |
|---|
| 775 | 08|tLes produits pharmaceutiques sur ordonnance au Canada : |w(CaOODSP)9.608046 |
|---|
| 830 | #0|aReport of the Standing Senate Committee on Social Affairs, Science and Technology ;|v[41st Parliament, 2nd Session, 15th report]|w(CaOODSP)9.505256 |
|---|
| 856 | 40|ahttp://publications.gc.ca|qPDF|s3308 KB|uhttps://publications.gc.ca/collections/collection_2014/sen/yc17-0/YC17-0-412-15-eng.pdf|y[41st Parliament, 2nd Session, 15th report] |
|---|